The patient’s grade 4 bullous pemphigoid emerges despite cabozantinib dose reduction, requiring high-dose corticosteroids and ...

Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions.

The causes of bullous pemphigoid, which typically develops at age 70 and older, are not fully understood. There is evidence that in some people, it may be triggered by medications.

Treatment with dupilumab led to significant improvements in disease remission in patients with bullous pemphigoid, an autoimmune blistering skin disease. The phase 2/3 LIBERTY-BP ADEPT trial ...

DPP4 inhibitors increased the risk of developing bullous pemphigoid in all age groups (multivariate analysis adjusted odds ratio [OR],1.58), but this risk was highest for those younger than 75 ...

DUBLIN--(BUSINESS WIRE)--The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. The "Bullous Pemphigoid - Pipeline Insight, 2023 ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly ...

Throughout the study period, 9304 patients were prescribed DPP4Is, and bullous pemphigoid developed in 8. Of those, 6 had a non-inflammatory form, and tests were negative for the antibody in 5.

Bullous pemphigoid is a rare autoimmune disease that causes painful chronic blisters and welts. it typically strikes elderly people who already have one or more diseases or are in poor health.

Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This "Bullous pemphigoid - Pipeline ...